The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long‐term outcome
Abstract
Objective: To evaluate the prevalence, clinical associations, and outcome of antiphospholipid syndrome (APS) nephropathy in patients with systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) and in SLE patients without aPL. Methods: Kidney biopsy specimens obtained from 81 patients with aPL (18 of whom had APS) and 70 patients without aPL were retrospectively examined for the presence of APS nephropathy. Clinical and serologic data obtained at the time of kidney biopsy and during a mean followup of 7 years were recorded. In cases for which serial kidney biopsy specimens were available, the evolution of APS nephropathy was examined. Results: APS nephropathy existed in 39.5% of patients with aPL, compared with only 4.3% of patients without aPL. APS nephropathy was associated with both lupus anticoagulant and anticardiolipin antibodies. Among aPL‐positive SLE patients, APS nephropathy was found in two‐thirds of those with APS and in one‐third of those without APS. A strong association between APS nephropathy and the presence of arterial thrombosis and livedo reticularis was noted. Patients with APS nephropathy had a higher frequency of hypertension and elevated serum creatinine levels at the time of kidney biopsy but did not have a higher frequency of renal insufficiency, end‐stage renal disease, or death at the end of followup. Serial kidney biopsy specimens were available from 11 patients and showed progression of APS nephropathy lesions. During followup, manifestations of APS (especially arterial thromboses) developed more frequently in the SLE/non‐APS patients with APS nephropathy than in those without APS nephropathy. Conclusion: Among patients with SLE, APS nephropathy occurs almost exclusively in those with aPL, suggesting an important role of aPL in the pathogenesis of APS nephropathy. Patients with APS nephropathy develop hypertension, raised serum creatinine levels, and progression of histologic lesions, all of which are associated with a poor renal outcome. Manifestations of APS also tend to develop in these patients. APS nephropathy should be included in the APS classification criteria, and the use of appropriate anticoagulant therapy should be tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
The “Primary” Antiphospholipid Syndrome: Major Clinical and Serological Features
ASHERSON, R. A., KHAMASHTA, M. A., ORDI-ROS, J., DERKSEN, R. H. W. M., MACHIN, S. J., BARQUINERO, J., OUTT, H. H., HARRIS, E. N., VILARDELL-TORRES, M., & HUGHES, G. R. V. (1989) · Medicine · doi:10.1097/00005792-198911000-00004 · Cited by 959
Prognostic factors in lupus nephritis
Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T., Kullick, M. E., Klippel, J. H., Decker, J. L., & Balow, J. E. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90338-8 · Cited by 803
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
The antiphospholipid syndrome: ten years on
Hughes, G. R. V. (1993) · The Lancet · doi:10.1016/0140-6736(93)91477-4 · Cited by 621
Finazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427
The Intrarenal Vascular Lesions Associated with Primary Antiphospholipid Syndrome
NOCHY, D., DAUGAS, E., DROZ, D., BEAUFILS, H., GRÜNFELD, J.-P., PIETTE, J.-C., BARIETY, J., & HILL, G. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103507 · Cited by 307
Cited by
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationBertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Self-citationInhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 265
MEHRANI, T., & PETRI, M. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100650 · Cited by 49
AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game
Canaud, G., Legendre, C., & Terzi, F. (2015) · Lupus · doi:10.1177/0961203315569336 · Cited by 32
Metadata
- Authors
- Tektonidou, M. G., Sotsiou, F., Nakopoulou, L., Vlachoyiannopoulos, P. G., & Moutsopoulos, H. M.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 50
- Issue
- 8
- Pages
- 2569-2579
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2034686952
- Cited by
- 255
- References
- 25
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.